The safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study
Abstract Background Ziprasidone mesylate injection is an atypical antipsychotic drug which is recently approved in China. In combination with its oral formulation, sequential therapy with ziprasidone brings new interventions to patients with agitation in the acute phase of schizophrenia. The purpose...
Main Authors: | Yaxue Wu, Yanli Li, Weiye Liang, Luyuan Bai, Jianjin Yu, Keqing Li, Yunshu Zhang, Yanmei Guo, Zenglong Liu, Jian Wang, Congpei Zhang, Xijin Wang, Jia Xu, Liping Liu, Juan Li, Fude Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-03-01
|
Series: | BMC Psychiatry |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12888-023-04588-0 |
Similar Items
-
Evaluation of intramuscular olanzapine and ziprasidone in the medically ill
by: Seema M. Patel, PharmD, BCPP, et al.
Published: (2021-01-01) -
Efficacy and Tolerability of Ziprasidone Use in Children and Adolescents, a Systemic Review and Meta Analysis
by: A. Wadhwa, et al.
Published: (2022-06-01) -
Comparison of intramuscular haloperidol and other short-acting injectable antipsychotics for management of acute agitation in an adult inpatient psychiatry unit
by: Sarah Gamcsik, PharmD, et al.
Published: (2024-08-01) -
Ziprasidone-induced stuttering: a case report
by: Sun Zhenxiao, et al.
Published: (2022-08-01) -
Drug eruption caused by ziprasidone: a case report
by: Hong Jiakun, et al.
Published: (2022-08-01)